Ipamorelin 10mg
Selective GH Secretagogue
Compound Overview
✓ Third-party COA published on arrival. Every batch of Ipamorelin is independently verified by HPLC-UV for purity and mass spectrometry for identity before release, with the batch-specific certificate posted to our Lab Results page. The current lot is ip10-0626-01, assayed by Janoshik Analytical (report #169441, June 2026) at 99.673% purity. Testides (Toronto) confirmation pending.
Ipamorelin (NNC 26-0161) is a selective growth hormone secretagogue — a pentapeptide agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a). It is frequently described in the literature as the first GH secretagogue to release growth hormone with high selectivity, meaning that in the foundational research it stimulated GH without meaningfully raising ACTH, cortisol, or prolactin — a profile that distinguishes it from earlier secretagogues such as GHRP-2 and GHRP-6.
Each vial contains 10mg of lyophilized Ipamorelin. CAS Number: 170851-70-4.
For a full scientific overview of Ipamorelin, see our Ipamorelin Research Guide or browse the Research Hub. To compare it with the paired compound, see the CJC-1295 + Ipamorelin guide.
Key research references
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552-561.
- Gobburu JVS, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999.
- Venkova K, et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. 2016 (PubMed 27186127).
For laboratory and research use only. Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada. All ThePeptide.ca materials are intended strictly for qualified research purposes. We do not provide preparation, dilution or administration guidance for any compound we sell.
Key specifications
See product label and the Overview tab.
Specifications
| Compound | Ipamorelin (NNC 26-0161) |
| Compound class | Selective growth hormone secretagogue — ghrelin / GHS-R1a receptor agonist |
| CAS number | 170851-70-4 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.85 g/mol |
| Amino acid sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide) |
| Vial contents | 10 mg lyophilized powder |
| Current lot | ip10-0626-01 (Janoshik report #169441, June 2026) |
| Verified purity | 99.673% (HPLC-UV) |
| Identity confirmation | Mass spectrometry confirmed |
| Storage | Lyophilized: -20°C long-term, 2-8°C short-term |
| Research applications | GHS-R1a receptor pharmacology, pulsatile GH-release models, secretagogue selectivity comparison (ACTH / cortisol / prolactin), gastric-motility research models |
| Related compounds | CJC-1295 + Ipamorelin (a separate, paired secretagogue + GHRH-analog product) |
| Ships from | British Columbia, Canada |
| Intended use | In-vitro laboratory research only |
Lab Results
- Sealed vial: −20°C, 24+ months.
- Protect from light and heat.
- Keep in original packaging until use in the laboratory.
Storage & Handling+
Ipamorelin is supplied as a lyophilized (freeze-dried) powder for maximum stability.
- Lyophilized (unopened): Store at -20°C long-term or 2-8°C short-term
- Light: Protect from direct light at all times
- Temperature cycling: Keep the sealed vial at a steady temperature and limit warm/cold swings. A manual-defrost freezer, or the back of a frost-free unit, holds a more stable temperature than a door shelf.
- Condensation: Let a cold, still-sealed vial come up to room temperature before the seal is broken, so atmospheric moisture does not condense onto the powder.
How fast does Ipamorelin ship in Canada, and is shipping free?+
Shipping is free on every order, Canada-wide, with no minimum order value, and every parcel is tracked. All orders ship from British Columbia, Canada.
- Processing: Dispatched within 48 hours (Mon-Fri)
- Delivery: Typically 2-8 business days anywhere in Canada
- Tracking: A tracking number is emailed as soon as your order ships
All research compounds are packaged in temperature-stable, tamper-evident materials. Vials are individually wrapped in discreet, unbranded packaging.
Returns & Refunds+
If your order arrives damaged or does not arrive within the expected timeframe, contact us at info@thepeptide.ca within 48 hours of the expected delivery date. Include your order number and photos of any damage.
Due to the nature of research compounds, we cannot accept returns on opened or prepared products. Sealed, unopened vials may be eligible for exchange within 14 days of delivery.
Frequently asked questions
Research Context & Mechanism+
Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Activation at the pituitary drives release of stored growth hormone in a pulsatile fashion. Because it acts as a secretagogue — prompting release of the body's own GH rather than supplying GH directly — it is studied as a tool compound for probing the GH axis.
Its defining characteristic in the literature is selectivity. In the foundational characterization by Raun and colleagues (1998), Ipamorelin released growth hormone with a potency comparable to GHRP-6, but — unlike GHRP-6 and GHRP-2 — did so without significant elevation of ACTH or cortisol, and without meaningfully affecting prolactin, FSH, LH, or TSH. This "clean" GH-selective profile is the reason it is often referenced as the first selective GH secretagogue.
Beyond the GH axis, Ipamorelin has been examined in gastrointestinal-motility research as a ghrelin-mimetic, including rodent models of postoperative ileus (gastric dysmotility).
Selectivity vs Other Secretagogues+
A common reason Ipamorelin appears in comparative research is its narrow hormonal footprint relative to earlier growth hormone-releasing peptides:
- GHRP-6: reported in the source literature to release GH, with concurrent orexigenic activity and elevation of cortisol/ACTH.
- GHRP-2 (pralmorelin): potent GH release, but with more pronounced ACTH, cortisol, and prolactin effects.
- Ipamorelin: GH release comparable to GHRP-6 in the original work, with ACTH and cortisol reported at or near baseline.
It is frequently studied alongside the GHRH analog CJC-1295, because a GHRH analog plus a GHS-R agonist act on two complementary pathways of the GH axis.
Development Status & Honest Limits+
Ipamorelin was originally developed by Novo Nordisk (as NNC 26-0161) and later investigated by Helsinn Therapeutics in Phase II trials for postoperative ileus. That clinical program was discontinued for lack of efficacy on its primary endpoint, and Ipamorelin has never been approved as a therapeutic drug. Most of the human GH-release data comes from small early-phase pharmacology studies rather than large controlled trials.
We flag this deliberately: the selectivity findings are well characterized in preclinical and early clinical work, but Ipamorelin remains an investigational research compound, not an approved medicine.
Purity & Third-Party Testing+
Every batch of Ipamorelin is independently tested using HPLC-UV for purity verification and mass spectrometry for molecular identity confirmation. The batch-specific Certificate of Analysis (COA) is published on our Lab Results page, and the current lot ip10-0626-01 was assayed by Janoshik Analytical (report #169441, June 2026) at 99.673% purity, as listed in the specifications table above. Testides (Toronto) confirmation pending.
New to reading a COA? See our guide on how to read a peptide certificate of analysis.
Mix anything in the store — the discount counts every unit in your whole order, not one product.
YOU MAY ALSO LIKE
SHOP ALL
Frequently Bought Together
Laboratory supplies commonly ordered alongside research compounds.
Bacteriostatic Water 10mL — Sterile Multi-Use Laboratory Water with 0.9% Benzyl Alcohol
Sterile Preserved Laboratory Water
